Drugs / IBI323
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04916119 | Jun 2021 → Jun 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05296278 | Dec 2023 → Dec 2025 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-12 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI-323 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05296278 ↗ |
| Action | Inhibit | “IBI323(anti-LAG-3/PD-L1)” NCT04916119 ↗ |
| Route | Intravenous | “IBI323 is administered by iv infusion day 1 of every 14 days.” NCT04916119 ↗ |